JW Therapeutics Announces NMPA Acceptance of the Supplemental New Drug Application for Carteyva® in Patients with Relapsed or Refractory Follicular Lymphoma
SHANGHAI, Feb. 27, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, announced that the National Medical Products Administration (NMPA) ofChina accepted the sup...
JW Therapeutics Announces Two Appointments to Strengthen R&D Capability and Pipeline Building
SHANGHAI, Jan. 10, 2022 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent, innovative biotechnology company focusing on developing, manufacturing and commercializing cell immunotherapy products, recently announced the appointments of Dr.Shaun Paul Cordoba as Chief Scientific Officer (...
JW Therapeutics Presents Primary Clinical Response on Carteyva(R) (relmacabtagene autoleucel injection) in Adults with Relapsed/Refractory Follicular Lymphoma in China at the 63rd ASH Annual Meeting
SHANGHAI, Dec. 15, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an independent innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, presented the primary clinical response on Carteyva® (relmacabtagene autoleucel injection) in...
JW Therapeutics Announces IND Approval for the Clinical Trial of JWCAR129
SHANGHAI, Sept. 27, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced that it has received the Investigational New Drug (IND) clearance from the National Medi...
JW Therapeutics Announces Updated 1-year Follow-up Result of Relmacabtagene Autoleucel Injection At the 24th Annual Meeting of the Chinese Society of Clinical Oncology (CSCO)
SHANGHAI, Sept. 26, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy products, today announced updated 1-year follow-up result of relmacabtagene autoleucel injection (relma-cel) for t...
JW Therapeutics Announces NMPA Approval of Relmacabtagene Autoleucel Injection in China
* The first CAR-T product independently developed in China and approved as a Category 1 biologics product, and the sixth approved CAR-T product globally * Currently the only approved CAR-T product that has been simultaneously included in the National Significant New Drug Development Program, g...
JW Therapeutics Announces Strategic Partnership with MediTrust Health
SHANGHAI, Aug. 20, 2021 /PRNewswire/ -- JW Therapeutics (HKEx: 2126), an innovative biotechnology company focused on developing, manufacturing and commercializing cell immunotherapy, today announced that it has entered into a strategic partnership with MediTrust Health. Leveraging the respective ...
JW Therapeutics Presents Data from Pivotal Trial of Relma-cel at the 62nd ASH Annual Meeting
SHANGHAI, Dec. 7, 2020 /PRNewswire/ -- JW Therapeutics (stock code: 2126.HK), a leading clinical stage cell therapy company, presented data from the pivotal study (RELIANCE Trial) of relmacabtagene autoleucel ("relma-cel") under IND pathway at the 62nd American Society of Hematology (ASH) Annual ...
Leading Cell Therapy Company JW Therapeutics Lists on Main Board of HKEX
SHANGHAI, Nov. 3, 2020 /PRNewswire/ -- JW Therapeutics (stock code: 2126.HK), a leading clinical stage cell therapy company inChina that focuses on developing, manufacturing and commercializing breakthrough cell-based immunotherapies for hematological cancers and solid tumors, today celebrates...
